Vaxart Ev To Sales from 2010 to 2024

VXRT Stock  USD 0.60  0.01  1.64%   
Vaxart EV To Sales yearly trend continues to be comparatively stable with very little volatility. EV To Sales will likely drop to 9.62 in 2024. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
10.12491809
Current Value
9.62
Quarterly Volatility
289.91616726
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 M, Interest Expense of 1.4 M or Total Revenue of 7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 2.34. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Vaxart Inc over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Vaxart's EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Vaxart Ev To Sales Regression Statistics

Arithmetic Mean118.56
Geometric Mean4.54
Coefficient Of Variation244.53
Mean Deviation187.62
Median1.20
Standard Deviation289.92
Sample Variance84,051
Range938
R-Value0.43
Mean Square Error73,444
R-Squared0.19
Significance0.11
Slope28.15
Total Sum of Squares1.2M

Vaxart Ev To Sales History

2024 9.62
2023 10.12
2022 937.09
2021 707.15
2020 95.03
2019 -0.37
2018 0.97

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as Ev To Sales, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EV To Sales 10.12  9.62 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.